Table 2.
Treatment and control peptides for in vitro and in vivo studies. The following table contains information on the sequences, MHC promiscuity, and parental protein location of the peptides and controls used in these studies.
| Peptide name | Amino acids | Sequence | HLA motifs | EpiMatrix cluster score | Location in IgG |
|---|---|---|---|---|---|
| hTregitope IgG-167 | 26 | PAVLQSSGLYSLSSVVTVPSSSLGTQ | 20 | 30.05 | CH1 |
| hTregitope IgG-289 | 21 | EEQYNSTYRVVSVLTVLHQDW | 14 | 22.57 | CH2 |
| mTregitope IgG-167 | 20 | PAVLQSDLYTLSSSVTVPSS | n/a | n/a | CH1 |
| mTregitope IgG-289 | 18 | EEQFNSTFRSVSELPIMHQ | n/a | n/a | CH2 |
|
| |||||
| mPPI 7–23 | 17 | FLPLLALLALWEPKPTQ | 11 | 18.69 | — |
| mPPI 20–35 | 16 | KPTQAFVKQHLCGPHL | 2 | −2.82 | — |
| mPPI 33–47 | 15 | PHLVEALYLVCGERG | 3 | −0.69 | — |
| mPPI 71–86 | 16 | SPGDLQTLALEVARQK | 0 | −6.59 | — |
| mPPI 77–92 | 16 | TLALEVARQKRGIVDQ | 2 | −3.1 | — |
|
| |||||
| TetTox 830–844 | 15 | QYIKANSKFIGITEL | 13 | 25.65 | — |
| Flu-HA 308–318 | 13 | PRYVKQNTLKLAT | 10 | 21.82 | — |
| OVA 323–339 | 17 | KISQAVHAAHAEINEAG | 4 | −0.39 | — |